Victory Capital Management Inc. Lowers Stock Holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Victory Capital Management Inc. decreased its position in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 56.7% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 11,832 shares of the company’s stock after selling 15,484 shares during the quarter. Victory Capital Management Inc.’s holdings in Intellia Therapeutics were worth $361,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of NTLA. ARK Investment Management LLC lifted its stake in shares of Intellia Therapeutics by 14.7% during the 4th quarter. ARK Investment Management LLC now owns 11,412,449 shares of the company’s stock valued at $347,966,000 after buying an additional 1,463,820 shares in the last quarter. Rhenman & Partners Asset Management AB lifted its stake in shares of Intellia Therapeutics by 1,600.0% during the 3rd quarter. Rhenman & Partners Asset Management AB now owns 850,000 shares of the company’s stock valued at $26,877,000 after buying an additional 800,000 shares in the last quarter. Federated Hermes Inc. lifted its stake in Intellia Therapeutics by 13.8% in the 4th quarter. Federated Hermes Inc. now owns 2,016,300 shares of the company’s stock worth $61,477,000 after purchasing an additional 244,722 shares in the last quarter. abrdn plc purchased a new stake in Intellia Therapeutics in the 4th quarter worth $4,704,000. Finally, Capital Advisors Inc. OK lifted its stake in Intellia Therapeutics by 34.7% in the 4th quarter. Capital Advisors Inc. OK now owns 284,738 shares of the company’s stock worth $8,682,000 after purchasing an additional 73,379 shares in the last quarter. Hedge funds and other institutional investors own 88.77% of the company’s stock.

Analyst Upgrades and Downgrades

NTLA has been the topic of several research analyst reports. Canaccord Genuity Group boosted their price target on shares of Intellia Therapeutics from $72.00 to $73.00 and gave the stock a “buy” rating in a research note on Friday, February 23rd. Wolfe Research initiated coverage on shares of Intellia Therapeutics in a research note on Thursday, February 15th. They issued a “peer perform” rating on the stock. Citigroup decreased their price target on shares of Intellia Therapeutics from $31.00 to $29.00 and set a “neutral” rating on the stock in a research note on Friday, May 10th. StockNews.com upgraded shares of Intellia Therapeutics to a “sell” rating in a research note on Friday, May 10th. Finally, BMO Capital Markets boosted their target price on shares of Intellia Therapeutics from $62.00 to $70.00 and gave the stock an “outperform” rating in a report on Friday, May 10th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and nine have issued a buy rating to the company’s stock. Based on data from MarketBeat, Intellia Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $66.77.

Intellia Therapeutics Trading Down 0.2 %

Shares of NASDAQ:NTLA opened at $24.84 on Friday. The company has a market capitalization of $2.40 billion, a price-to-earnings ratio of -4.63 and a beta of 1.85. Intellia Therapeutics, Inc. has a 12 month low of $19.37 and a 12 month high of $47.48. The firm’s 50-day moving average is $24.59 and its 200 day moving average is $27.18.

Intellia Therapeutics (NASDAQ:NTLA) last issued its quarterly earnings results on Thursday, February 22nd. The company reported ($1.46) EPS for the quarter, beating the consensus estimate of ($1.47) by $0.01. The company had revenue of ($1.92) million for the quarter, compared to the consensus estimate of $15.10 million. Intellia Therapeutics had a negative net margin of 893.34% and a negative return on equity of 45.35%. During the same period in the prior year, the firm posted ($1.40) EPS. As a group, equities analysts forecast that Intellia Therapeutics, Inc. will post -5.12 EPS for the current fiscal year.

Insider Buying and Selling at Intellia Therapeutics

In other Intellia Therapeutics news, EVP James Basta sold 2,297 shares of the business’s stock in a transaction dated Monday, March 4th. The shares were sold at an average price of $32.99, for a total value of $75,778.03. Following the completion of the sale, the executive vice president now directly owns 81,571 shares of the company’s stock, valued at approximately $2,691,027.29. The transaction was disclosed in a filing with the SEC, which is available through this link. 3.00% of the stock is owned by corporate insiders.

Intellia Therapeutics Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.